Antibody Drug Conjugates (ADCs) offer the potential of highly selective targeting of monoclonal antibodies (mAbs) with the targeted delivery of cytotoxic drugs. ADCs  comprise of three components and are produced by covalently linking a monoclonal antibody via a chemical linker to small molecule potent cytotoxic drugs. The inherent complexity of the mAb component combined with the added variability introduced by the distribution of drug linked forms presents a range of complex analytical challenges that must be addressed to achieve successful drug development ensuring a safe and effective drug product.

Download our Whitepaper: The Complexities of Antibody Drug Conjugate Characterization